Cargando…
Loss of Trop2 causes ErbB3 activation through a neuregulin-1-dependent mechanism in the mesenchymal subtype of HNSCC
In head and neck squamous cell cancer (HNSCC), four intrinsic subtypes (or groups) have been identified, and each one possesses a unique biology that will require specific treatment strategies. We previously reported that mesenchymal (group 2) tumors exhibit reduced levels of Trop2 expression. In th...
Autores principales: | Zhang, Kaihua, Jones, Lamont, Lim, Sora, Maher, Christopher A., Adkins, Douglas, Lewis, James, Kimple, Randall J., Fertig, Elana J., Chung, Christine H., Herrlich, Andreas, Ellis, Matthew J., Van Tine, Brian A., Michel, Loren S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4253434/ https://www.ncbi.nlm.nih.gov/pubmed/25238142 |
Ejemplares similares
-
Anti-Trop2 blockade enhances the therapeutic efficacy of ErbB3 inhibition in head and neck squamous cell carcinoma
por: Redlich, Nathan, et al.
Publicado: (2018) -
ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC
por: Alvarado, Diego, et al.
Publicado: (2017) -
On the Modulatory Roles of Neuregulins/ErbB Signaling on Synaptic Plasticity
por: Ledonne, Ada, et al.
Publicado: (2019) -
Clozapine-dependent inhibition of EGF/neuregulin receptor (ErbB) kinases
por: Kobayashi, Yutaro, et al.
Publicado: (2019) -
Neuregulin-1-mediated ErbB2–ErbB3 signalling protects human trophoblasts against apoptosis to preserve differentiation
por: Fock, Valerie, et al.
Publicado: (2015)